期刊文献+

基质金属蛋白酶及其抑制物在胸腔积液中的表达 被引量:2

Expression of matrix metalloproteinase and tissue inhibitorof metalloproteinase in pleural effusion
下载PDF
导出
摘要 目的检测良、恶性胸腔积液中MMP-2、MMP-9、TIMP-2的含量以及MMP-2/TIMP-2比值为鉴别良、恶性胸腔积液提供依据。方法收集胸腔积液患者153例,其中漏出液(心力衰竭25例、低蛋白血症17例)42例,结核性胸腔积液54例,恶性胸腔积液57例,采用酶联免疫吸附法(ELISA法)分别检测胸水中MMP-2、MMP-9、TIMP-2的含量以及MMP-2/TIMP-2比值。结果结核性胸腔积液组中MMP-2、MMP-9、TIMP-2含量依次为(99.65±26.30)μg/L、(62.92±5.56)μg/L、(88.81±25.65)μg/L,显著高于漏出液组MMP-2、MMP-9、TIMP-2含量(64.55±12.18)μg/L,(62.92士5.56)μg/L,(10.67士3.02)μg/L,(41.43±11.27)μg/L,P<0.01;显著低于恶性胸腔积液组MMP-2、MMP-9、TIMP-2含量(121.23±14.09)μg/L,(31.12±4.05)μg/L、(108.43士16.37)μg/L,P<0.01。结核性胸腔积液组中MMP-2/TIMP-2(1.40±0.24)低于漏出液组(1.62±0.22),高于恶性胸腔积液组(1.14±0.27),P>0.05。结论在恶性胸水中MMP-2、MMP-9、TIMP-2含量明显升高;MMP-2、MMP-9、TIMP-2以及可作为良、恶性胸水的鉴别指标。 Objective To study the expression of MMP-2、MMP-9、TIMP-2 and MMP-2/TIMP-2 proteins in pleural effusion and analyse the difference between benign and malignant pleural effusion.Methods One hundred and fifty-three patients with pleural effusion were collected: 42 patients with transudate(25 patients from heart failure,17 patients from hypoproteinemia),54 patients with tuberculous pleural effusion,57 patients with malignant pleural effusion.All of levels of MMP-2,MMP-9,TIMP-2 were detected by enzyme-linked immunosorbent assay(ELISA) method.Results Levels of MMP-2,MMP-9 and TIMP-2[(99.65±26.30)μg/L,(31.12±4.05)μg/L,(88.81±25.65)μg/L] in the patients with tuberculous pleural effusion were significantly higher than those in transudate[(64.55±12.18)μg/L,(10.67±3.02)μg/L,(41.43±11.27)μg/L,P0.01];But they were significantly lower than those in malignant pleural effusion[(121.23±14.09)μg/L,62.925.56)μg/L,(108.43±16.37)μg/L,P0.01].Ratios of MMP-2/TIMP-2(1.40±0.24) in the patients with tuberculous pleural effusion were lower than those in transudate(1.62±0.22).But they were higher than those in malignant pleural effu-sion(1.14±0.27,P0.05).Conclusion Levels of MMP-2、MMP-9 and TIMP-2 in the patients with malignant pleural effusion are high remarkably.MMP-2,MMP-9,TIMP-2 are the standards to distinguish tuberculous pleural effusion and malignant characters.
出处 《哈尔滨医科大学学报》 CAS 北大核心 2010年第5期475-477,共3页 Journal of Harbin Medical University
关键词 基质金属蛋白酶 基质金属蛋白酶抑制物 胸腔积液 恶性 结核性胸腔积液 matrix metalloproteinase tissue inhibitor of metalloproteinase pleural effusion malignant tuberculous pleural effusion
  • 相关文献

参考文献8

  • 1Emara M,Cheung PY,Grabowski K,et al.Serum levels of matrix metalloproteinase-2 and-9 and conventional tumor markers (CEA and CA 19-9) in patients with colorectal and gastric cancers[J].Clin Chem Lab Med,2009,47(8):993-1000.
  • 2Pancewicz SA,Lzycka A,Klibingat M,et al.Transforming growth factor beta,metalloproteinase 2 and its tissue inhibitor 2 in the serum from patients with early and late boreliosis[J].Pol Merkur Lekarski,2008,25(150):495-499.
  • 3Olszynski K,Zimowska M.Structure and function of matrix metalloproteinases[J].Postepy Biochem,2009,55(1):76-84.
  • 4Martinez-Alvernia EA,Mankarious LA.Matrix metalloproteinases 2 and 9 are concentrated in the luminal aspect of the cricoid cartilage,diminish with loss of perichondrium,and are reinstated by transforming growth factor beta 3[J].Ann Otol Rhinol Laryngol,2008,117(12):925-930.
  • 5Keibel A,Singh V,Sharma MC.Inflammation,microenvironment,and the immune system in cancer progression[J].Curr Pharm Des,2009,15(17):1949-1955.
  • 6Offenberg H,Breuner N,Mansilla F,et al.TIMP-1 expression in human colorectal cancer is associated with TGF-B1,LOXL2,INHBA1,TNF-AIP6 and TIMP-2 transcript profiles[J].Mol Oncol,2008,2(3):233-240.
  • 7Montiel M,Urso L,de la Blanca EP,et al.Cisplatin reduces endothelial cell migration via regulation of type 2-matrix metalloproteinase activity[J].Cell Physiol Biochem,2009,23(4-6):441-448.
  • 8Bezuglova TV,Poliakova GA,Kazantseva IA.Role of immunohistochemical study of extracellular matrix components in the estimation of the malignant potential of adrenal pheochromocytomas[J].Arkh Patol,2008,70(6):19-21.

同被引文献33

  • 1孙瑜,王良兴,王惠军,李翊卫.VEGF、CD44_(V6)、MMP联合检测对良、恶性胸水的鉴别意义[J].温州医学院学报,2006,36(4):350-353. 被引量:6
  • 2Wardwell NR,Massion PP.Novel strategies for the early detec-tion and prevention of lung cancer.Semin Oncol,2005,32(3):259-268.
  • 3Christian w,Matthias N.Cancer Invasion and Metastasi[s J].Oncol,2005,69(suppl.1):14-16.
  • 4Singh RD,Haridas N,Patel JB,Shah FD,Shukla SN,Shah PM,Patel PS.Matrix metalloproteinases and their inhibitors:correlation withinvasion and metastasis in oral cancer.Indian J Clin Biochem.2010,25:250-259.
  • 5Lukaszewicz-Zajac M,Mroczko B,Szmitkowski M[.The signifi-cance of metalloproteinases and their inhibitors in gastric cancer].PostepyHig Med Dosw(Online),2009,63:258-265.
  • 6Altadill A,Rodríguez M,González LO,JunqueraS,CorteMD,González-Dieguez ML,Linares A,Barbón E,Fresno-ForcelledoM,Rodrigo L,Vizoso FJ.Liver expression of matrix metalloproteases andtheir inhibitors in hepatocellular carcinoma.Dig Liver Dis,2009,41:740-748.
  • 7Visse R,Nagase H.Matrix metalloproteinases and tissue inhibitorsof metalloproteinases-Structure,function,and biochemistry[J].Circ Res,2003,92(8):827-839.
  • 8Egeblad M,Werb Z.New functions for the matrix metallopro-teinases in cancer progression[J].Nat Rev Cancer,2002,2(3):161-174.
  • 9Brown RD,Jones GM,Laird RE,et al.Cytokines reguhte Matrixmetalloproteinases and migration in cardiac fibroblasts[J].Biochem Biop-bys Bes Commun,2007,362(1):200-205.
  • 10Han S,Ritzenthaler JD,Sitaraman SV,et a1.Fibronectin increas-es matrix metalloproteinase 9 expression through activation of c-Fos viaextracellular-regulated kinase and phosphatidylinositol 3-kinase pathwaysin human lung carcinoma cells.J Biol Chem,2006,281:29614-29624.

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部